COGT in the 13F filings
Cogent Biosciences Inc · CUSIP 19240Q201
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 14 Nov 2023
- latest of these filings; the earliest 14 Nov 2023
- Managers listing it
- 4
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 3 listed it in both
- Shares listed
- 6,091,053
- combined, among listed positions
- Reported value
- $59m
- combined, at the quarter end
Managers listing COGT in Q3 2023
4 of 4 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Point72 Asset Management LP | 3,766,755 | $37m | 0.11% | Trimmed | -918,299 | 14 Nov 2023 (the filing on sec.gov) |
| Marshall Wace LLP | 2,187,298 | $21m | under 0.1% | Added | +33,211 | 14 Nov 2023 (the filing on sec.gov) |
| Woodline Partners LP | 120,000 | $1.2m | under 0.1% | New | new | 14 Nov 2023 (the filing on sec.gov) |
| Farallon Capital Management LLC | 17,000 | $166k | under 0.1% | Trimmed | -966,452 | 14 Nov 2023 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Woodline Partners LPnew position · 120,000 shares now+120,000
- Marshall Wace LLPexisting position · 2,187,298 shares now+33,211
Reductions
- Farallon Capital Management LLCexisting position · 17,000 shares now-966,452
- Point72 Asset Management LPexisting position · 3,766,755 shares now-918,299
New positions and exits
New (1)
- Woodline Partners LP$1.2m
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 2 | $8.0m | n.a. | n.a. |
| Q1 2021 | 2 | $6.4m | n.a. | n.a. |
| Q2 2021 | 2 | $17m | n.a. | n.a. |
| Q3 2021 | 1 | $5.0m | n.a. | n.a. |
| Q4 2021 | 1 | $5.1m | n.a. | n.a. |
| Q1 2022 | 1 | $6.4m | n.a. | n.a. |
| Q2 2022 | 1 | $9.0m | n.a. | n.a. |
| Q3 2022 | 1 | $3.7m | n.a. | n.a. |
| Q4 2022 | 3 | $11m | n.a. | n.a. |
| Q1 2023 | 4 | $63m | n.a. | n.a. |
| Q2 2023 | 3 | $93m | n.a. | n.a. |
| Q3 2023 | 4 | $59m | n.a. | n.a. |
| Q4 2023 | 3 | $35m | 2 | 0 |
| Q1 2024 | 3 | $53m | 2 | 1 |
| Q2 2024 | 4 | $97m | 2 | 2 |
| Q3 2024 | 4 | $120m | 1 | 1 |
| Q4 2024 | 4 | $47m | 1 | 1 |
| Q1 2025 | 3 | $42m | 1 | 1 |
| Q2 2025 | 3 | $43m | 0 | 2 |
| Q3 2025 | 4 | $92m | 2 | 1 |
| Q4 2025 | 9 | $1.3bn | 24 | 5 |
| Q1 2026 | 11 | $1.6bn | 21 | 13 |
| Q2 2026 | 7 | $1.6bn | 17 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
COGT and LLY →COGT and JNJ →COGT and VRTX →Choose a stock to compare with COGT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own COGT, latest filings →Back to the 13F Explorer →